Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Recap: Nikkei (0.01%), Hang Seng (1.00%), Shanghai Composite (0.54%) as of 04:10 ET

Sep 15 ,2026

  • Synopsis:

    • Asian equities lower Tuesday. Hang Seng fell to two-month low and led losses in Greater China markets. South Korea and Taiwan also declined as AI trade remained volatile following preceding selloff. Nikkei was flat. Singapore was worst performer in Southeast Asia. India trading lower after long weekend. US futures also down. Bond selloff continues with Treasury and JGB yield curves steepening. Crude strengthening as Brent approaches $108/bl while gold and silver continue to slip. Dollar firmer against other majors, at one-week high against yen. Bitcoin retreating.

    • Rising bond yields were key market focus during Asian session with 10Y Treasury yield surpassing 2023 peak and rising to highest since 2007, latest milestone in relentless global bond selloff driven by elevated oil prices and associated concerns about inflation pass-through, hawkish shift in monetary policy expectations, widening fiscal deficits, and AI-driven ramp in corporate issuance. Bond slump increases stakes ahead of FOMC meeting with markets pricing in 90% chance of a rate hike, which will be first time since Jul-23. Analysts warned bond investors may demand even higher yields if Fed doesn't hike or Chairman Walsh signals more dovish stance in coming months than what's priced in by money markets. In another major development, investors assessing outlook for AI-related stocks as there was no bounce for AI stocks following Monday's selloff that came after Anthropic's call to slow pace of model development, which invited pushback from both President Trump and China.

    • China's August activity data came mixed, which underlined continued weakness in domestic consumption. Retail sales growth unexpectedly slowed, weighed down by autos. Fixed asset investment declined with infrastructure going backward. Property metrics weak with real estate investment declining 20%, home price declines maintaining prior months' pace and credit metrics showing sharp drop in personal lending. Industrial production was a bright spot and rose by more than forecast, driven by high-tech manufacturing sectors. Strong industrial output also corroborated China's booming exports amid booming global demand for AI-related products. More economists expected economic growth at risk of falling below official target of 4.5% to 5% as policymakers under growing pressure to deploy more stimulus. Elsewhere Japan's cabinet approved plan to temporarily reduce consumption tax on food to 1% from 8% for two years and Tokyo considering new mid-term defense spending target of 3.5% of GDP.

    • Kioxia (285A.JP) said details of its ADR listings have not been determined yet after Bloomberg reported company considering raising at least $10B in US offering that may take place next year. CATL (3750.HK) gets regulatory approval to acquire battery firm linked with Geely Auto (175.HK), indicating China's backing for battery sector consolidation. CATL shares fell 6%, worst performer in Hang Seng Index. GAC Group (2238.HK) resumed trading Tuesday and rose 2.6% after company announced it plans to issue A-share to acquire equity in JV automaker FAW Toyota held by China's FAW Group.

  • Digest:

    • Notable Gainers:

      • +29.9% 424870.KS (Immuneoncia Therapeutics): Korea's MFDS approves ImmuneOncia Therapeutics' IND amendment for phase 1 trial of IMC-002

      • +2.6% 2238.HK (Guangzhou Automobile Group): to acquire stake in China FAW Group's joint venture in all-stock deal

      • +2.3% 285A.JP (Kioxia Holdings): reportedly considering raising ~$10B in US listing

      • +1.9% 4502.JP (Takeda Pharmaceutical): FDA accepts NDA of zasocitinib under priority review

    • Notable Decliners:

      • -4.8% 9627.JP (Ain Holdings): reports Q1 results; operating profit below FactSet estimates

      • -2.3% 960.HK (Longfor Group Holdings): China new-home prices in 70 major cities (0.17%) m/m in August vs month-ago (0.18%) m/m

      • -1.1% 042700.KS (HANMI Semiconductor): reportedly to supply packaging equipment for system semiconductors to TeraFab

      • -1% 9435.JP (Hikari Tsushin): offers to acquire Leopalace21 at ¥1,000/share

  • Data:

    • Economic:

      • China August

        • Industrial production +5.2% y/y vs consensus +4.8% and +4.5% in prior month

        • Retail sales +0.4% y/y vs consensus +0.8% and +0.6% in prior month

        • Fixed asset investment (YTD) (7.2%) y/y vs consensus (7.1%) and (6.7%) in prior month

        • Unemployment rate 5.3% vs consensus 5.2% and 5.2% in prior month

        • New house prices (0.1%) m/m vs (0.1%) in prior month

    • Markets:

      • Nikkei: (8.89) or (0.01%) to 63484.10

      • Hang Seng: (250.36) or (1.00%) to 24667.24

      • Shanghai Composite: (21.05) or (0.54%) to 3864.28

      • Shenzhen Composite: (20.25) or (0.82%) to 2444.04

      • ASX200: (77.40) or (0.88%) to 8672.50

      • KOSPI: (57.11) or (0.85%) to 6627.26

      • SENSEX: (279.20) or (0.37%) to 74502.56

    • Currencies:

      • $-¥: +0.83 or +0.54% to 155.1750

      • $-KRW: +15.43 or +1.14% to 1363.2700

      • A$-$: (0.00) or (0.29%) to 0.7119

      • $-INR: +0.10 or +0.11% to 95.9366

      • $-CNY: (0.00) or (0.00%) to 6.7142

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.